Abivax’s lead therapeutic candidate ABX464 demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients as measured by total HIV DNA detected in peripheral blood mononuclear cells (PBMCs).
French bio-pharmaceutical company Onxeo and the Institut Curie have collaborated to launch a series of studies aimed to investigate the benefits of combining radiotherapy, DNA repair inhibitors and immunotherapy for cancer patients.